Hypercalcaemia in alphacalcidol therapy
Open Access
- 1 July 1981
- journal article
- research article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 57 (669) , 431-432
- https://doi.org/10.1136/pgmj.57.669.431
Abstract
Summary: Three women with hypoparathyroidism are described who developed severe symptomatic hypercalcaemia while being treated with alphacalcidol (1 alpha-hydroxycholecalciferol; One-Alpha). One sustained permanent renal damage. Alphacalcidol may have advantages over calciferol in its speed of action but poisoning may be more likely to occur. Frequent follow-up checks on the plasma calcium is needed for any patient on alphacalcidol. For long-term management calciferol may still be the drug of choice.This publication has 11 references indexed in Scilit:
- VITAMIN-D POISONING: SURVEY OF CAUSES IN 21 PATIENTS WITH HYPERCALCÆMIAThe Lancet, 1980
- VITAMIN-D ANALOGUES AND RENAL FUNCTIONThe Lancet, 1979
- THE CONTINUING RISK OF VITAMIN-D INTOXICATIONThe Lancet, 1978
- STUDIES OF HYPOPARATHYROIDISM AND PSEUDOHYPOPARATHYROIDISM1978
- Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives.BMJ, 1977
- 1-ALPHA-HYDROXYCHOLECALCIFEROL IN THE TREATMENT OF HYPOCALCAEMIC PSYCHOSISClinical Endocrinology, 1976
- Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.Journal of Clinical Investigation, 1976
- Effects of 1α-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 on calcium and phosphorus metabolism in hypoparathyroidismMetabolism, 1975
- Treatment of Hypoparathyroidism and Pseudohypoparathyroidism with Metabolites of Vitamin D: Evidence for Impaired Conversion of 25-Hydroxyvitamin D to 1α,25-Dihydroxyvitamin DNew England Journal of Medicine, 1975
- 1,25-DIHYDROXYCHOLECALCIFEROL AND 1α-HYDROXYCHOLECALCIFEROL IN HYPOPARATHYROIDISMThe Lancet, 1974